Alpha 2.0
Login Register
» Articles » PMID: 15140115

Is the Incidence and Prevalence of Inhibitors Greater with Recombinant Products? Yes

Overview
Journal J Thromb Haemost
Publisher Elsevier
Specialty Hematology
Date 2004 May 14
PMID 15140115
Citations 9
Authors
L M Aledort
Affiliations
Soon will be listed here.
Citing Articles

Plasma-derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study.

Bravo M, Perez A, Raventos A, Grancha S, Jorquera J, Butta N Haemophilia. 2022; 28(5):737-744.

PMID: 35654086 PMC: 9545517. DOI: 10.1111/hae.14589.

Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.

Peyvandi F, Miri S, Garagiola I Front Immunol. 2021; 11:591878.

PMID: 33552050 PMC: 7862552. DOI: 10.3389/fimmu.2020.591878.

Product type and other environmental risk factors for inhibitor development in severe hemophilia A.

Peyvandi F, Garagiola I Res Pract Thromb Haemost. 2018; 2(2):220-227.

PMID: 30046724 PMC: 6055565. DOI: 10.1002/rth2.12094.

Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders.

Di Minno G, Perno C, Tiede A, Navarro D, Canaro M, Guertler L Blood Rev. 2015; 30(1):35-48.

PMID: 26381318 PMC: 7115716. DOI: 10.1016/j.blre.2015.07.004.

Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.

Oldenburg J, Lacroix-Desmazes S, Lillicrap D Haematologica. 2015; 100(2):149-56.

PMID: 25638804 PMC: 4803147. DOI: 10.3324/haematol.2014.112821.